Shang­hai biotech up­start rais­es $50M, bags an­ti­body dis­cov­ery group and ramps up Boston unit

A new Shang­hai-based biotech up­start is tak­ing part of its $50 mil­lion A round to ac­quire an an­ti­body dis­cov­ery out­fit in Rot­ter­dam while blue­print­ing plans to jump­start a re­search site in the Boston area.

The Chi­nese com­pa­ny is Har­bour Bio­Med, run by Sanofi R&D vet Jing­song Wang and Liang Schweiz­er. They are buy­ing Har­bour An­ti­bod­ies, a spin­out of Eras­mus Uni­ver­si­ty which has been do­ing a se­ries of deals us­ing its trans­genic mouse mod­els to dis­cov­er new an­ti­bod­ies. And they are be­ing fi­nanced by Ad­van­tech Cap­i­tal and Leg­end Cap­i­tal, two in­creas­ing­ly promi­nent Chi­na-based life sci­ences in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER